Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era.
about
Hsp90 Inhibitors for the Treatment of Chronic Myeloid LeukemiaJAK2 (V617F) Positive Latent Myeloproliferative Neoplasm Presenting with Splanchnic Vein ThrombosisOptimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms.Polycythemia vera presenting as acute myocardial infarction: An unusual presentationScreening for hotspot mutations in PI3K, JAK2, FLT3 and NPM1 in patients with myelodysplastic syndromes.Development of a novel, fully-automated genotyping system: principle and applications.Extramedullary Involvement by Chronic Myelogeneous Leukemia in Five Patients With Unusual Clinicopathologic Features: A Review of the Effectiveness of Tyrosine Kinase InhibitorsBone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres.JAK2-V617F-induced MAPK activity is regulated by PI3K and acts synergistically with PI3K on the proliferation of JAK2-V617F-positive cellsClinical implications of JAK2 mutations in myeloproliferative disorders.The JAK2(V617F) tyrosine kinase mutation in blood donors with upper-limit haematocrit levels.Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms.Therapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosisThree important components in the regeneration of the cavernous nerve: brain-derived neurotrophic factor, vascular endothelial growth factor and the JAK/STAT signaling pathwayMyeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?Advances in molecular diagnostics of myeloproliferative disorders.MicroRNAs in Myeloid Hematological Malignancies.On the Power of Additional and Complex Chromosomal Aberrations in CML.Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients.Detecting the JAK2 V617F mutation in fresh and 'historic' blood and bone marrow.
P2860
Q26771790-D9699022-5D22-4F68-80ED-8E7A817491BCQ30303071-6100F3AE-A09F-4C27-94FE-5CC6F6C1AA9EQ33771667-8A5948A6-048E-494D-AC7E-2336FBD327B6Q34759712-1E526967-53B7-46AB-92ED-10FBD3EFA5A6Q35028968-78DFD97D-D8C2-4126-B501-498D2128E8D2Q36608218-16642053-0556-461D-AF3B-CFB3EA01CA8AQ36856998-3A0657A5-A439-4B08-BC56-A26F3622D130Q36957972-EF758F8E-3192-4D7A-9E78-38E83EC63146Q37168132-2644903C-5A6D-491C-922B-E4B5B463056FQ37198841-99D78627-9BDA-4AD6-A67E-F25C392EE00FQ37209108-591788E1-DB3C-424E-929C-1E806DB4DDB9Q37483993-4561CB16-47E8-4C8E-B81F-721074CD835AQ37705695-63BD11B0-CC3C-42B9-943D-811E21A02A92Q37822274-E71B203A-4DF6-4C52-9977-68224186095AQ37877727-6C5F063F-DBA5-4F12-8290-4BEA6D715010Q38089228-64077459-F57E-4E36-996B-3B6B7F3055FCQ38599595-824F83DD-F680-4DBA-9D3A-792E39AE7A7EQ42321082-D9C206DE-B2CC-4D0A-B86A-4BE8D7A6B3D9Q46190174-22BC7835-EF62-46AD-BABF-71074AA484C8Q47791718-F7280C7C-05EB-48F1-A818-89E71856992A
P2860
Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
name
Classification, diagnosis and ...... isorders in the JAK2V617F era.
@ast
Classification, diagnosis and ...... isorders in the JAK2V617F era.
@en
Classification, diagnosis and ...... isorders in the JAK2V617F era.
@nl
type
label
Classification, diagnosis and ...... isorders in the JAK2V617F era.
@ast
Classification, diagnosis and ...... isorders in the JAK2V617F era.
@en
Classification, diagnosis and ...... isorders in the JAK2V617F era.
@nl
prefLabel
Classification, diagnosis and ...... isorders in the JAK2V617F era.
@ast
Classification, diagnosis and ...... isorders in the JAK2V617F era.
@en
Classification, diagnosis and ...... isorders in the JAK2V617F era.
@nl
P1476
Classification, diagnosis and ...... isorders in the JAK2V617F era.
@en
P304
P356
10.1182/ASHEDUCATION-2006.1.240
P577
2006-01-01T00:00:00Z